Company Description
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy.
The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Dr. Allen Warren Davidoff Ph.D. |
Contact Details
Address: Suite 2400 - 745 Thurlow Street Vancouver, A1 V6E 0C5 British Columbia, Canada | |
| Phone | 403-607-2621 |
| Website | xortx.com |
Stock Details
| Ticker Symbol | XRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001729214 |
| CUSIP Number | 98420Q207 |
| ISIN Number | CA98420Q3061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, Chief Executive Officer, President and Director |
| James Neville Fairbairn C.A., C.P.A., ICD.D | Interim Chief Financial Officer |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Nick Rigopoulos | Director of Communications |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Charlotte May | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Mar 27, 2024 | 6-K | Report of foreign issuer |
| Mar 20, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 3, 2024 | 6-K | Report of foreign issuer |
| Jan 2, 2024 | 6-K | Report of foreign issuer |
| Nov 30, 2023 | 6-K | Report of foreign issuer |
| Nov 30, 2023 | 6-K | Report of foreign issuer |